Evidence That Replication of the Antitumor Adenovirus ONYX-015 is Not Controlled by the P53 and P14(ARF) Tumor Suppressor Genes

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2002 Nov 20

PMID 12438574

Citations 27

Authors

Sara J Edwards

Brett R Dix

Colleen J Myers

Deirdre Dobson-Le

Lily Huschtscha

Merilyn Hibma

Janice Royds

Antony W Braithwaite

Affiliations

Soon will be listed here.

Abstract

The adenovirus mutant ONYX-015 is in phase III clinical trials as a novel antitumor therapy. Its apparent efficacy is thought to be due to its ability to replicate selectively in tumor cells defective in the signaling pathway for p53. Recent data have shown that p14(ARF), a positive regulator of p53, inhibits ONYX-015 replication in cells with a wild-type p53, a phenotype that characterizes normal cells. We, however, found that ONYX-015 activates p53 in tumor cells and in normal cells and that this can occur without p14(ARF) induction. We also show that ONYX-015 is not attenuated in cells with functional p53, whether or not p14(ARF) is expressed, and that where attenuation does occur, it is cell type specific.

Citing Articles

Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin.

Chen S, Wang C, Huang T, Tsai J, Wang H, Yen Y Cells. 2024; 13(18.

PMID: 39329778 PMC: 11430802. DOI: 10.3390/cells13181597.

Clinical Application of Adenovirus (AdV): A Comprehensive Review.

Salauddin M, Saha S, Hossain M, Okuda K, Shimada M Viruses. 2024; 16(7).

PMID: 39066256 PMC: 11281619. DOI: 10.3390/v16071094.

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma.

Hu M, Liao X, Tao Y, Chen Y Front Immunol. 2023; 14:1285113.

PMID: 38022620 PMC: 10652401. DOI: 10.3389/fimmu.2023.1285113.

Adenoviral Gene Therapy Vectors in Clinical Use-Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety.

Leikas A, Yla-Herttuala S, Hartikainen J Int J Mol Sci. 2023; 24(22).

PMID: 38003709 PMC: 10671366. DOI: 10.3390/ijms242216519.

Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives.

Meliante P, Petrella C, Fiore M, Minni A, Barbato C Curr Issues Mol Biol. 2023; 45(11):9215-9233.

PMID: 37998754 PMC: 10670496. DOI: 10.3390/cimb45110577.

References

Babiss L, Ginsberg H, Darnell Jr J . Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol Cell Biol. 1985; 5(10):2552-8. PMC: 366989. DOI: 10.1128/mcb.5.10.2552-2558.1985. View

Yew P, Liu X, Berk A . Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 1994; 8(2):190-202. DOI: 10.1101/gad.8.2.190. View

OCarroll S, Hall A, Myers C, Braithwaite A, Dix B . Quantifying adenoviral titers by spectrophotometry. Biotechniques. 2000; 28(3):408-10, 412. DOI: 10.2144/00283bm03. View

Dix B, OCarroll S, Myers C, Edwards S, Braithwaite A . Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res. 2000; 60(10):2666-72. View

Turnell A, Grand R, Gorbea C, Zhang X, Wang W, Mymryk J . Regulation of the 26S proteasome by adenovirus E1A. EMBO J. 2000; 19(17):4759-73. PMC: 302057. DOI: 10.1093/emboj/19.17.4759. View

Ries S, Brandts C, Chung A, Biederer C, Hann B, Lipner E . Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000; 6(10):1128-33. DOI: 10.1038/80466. View

Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T . Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000; 60(22):6359-66. View

Heise C, Lemmon M, Kirn D . Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res. 2001; 6(12):4908-14. View

Dix B, Edwards S, Braithwaite A . Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?. J Virol. 2001; 75(12):5443-7. PMC: 114255. DOI: 10.1128/JVI.75.12.5443-5447.2001. View

10.

Gallimore P, Turnell A . Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene. 2001; 20(54):7824-35. DOI: 10.1038/sj.onc.1204913. View

11.

Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe M . Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 2002; 62(3):764-72. View

12.

Pilder S, Moore M, Logan J, Shenk T . The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol Cell Biol. 1986; 6(2):470-6. PMC: 367535. DOI: 10.1128/mcb.6.2.470-476.1986. View

13.

Barker D, Berk A . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 1987; 156(1):107-21. DOI: 10.1016/0042-6822(87)90441-7. View

14.

Masuda H, Miller C, Koeffler H, Battifora H, Cline M . Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A. 1987; 84(21):7716-9. PMC: 299371. DOI: 10.1073/pnas.84.21.7716. View

15.

Whyte P, Buchkovich K, Horowitz J, Friend S, Raybuck M, Weinberg R . Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature. 1988; 334(6178):124-9. DOI: 10.1038/334124a0. View

16.

Braithwaite A, Blair G, Nelson C, McGovern J, BELLETT A . Adenovirus E1b-58 kD antigen binds to p53 during infection of rodent cells: evidence for an N-terminal binding site on p53. Oncogene. 1991; 6(5):781-7. View

17.

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

18.

Yew P, Berk A . Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 1992; 357(6373):82-5. DOI: 10.1038/357082a0. View

19.

Momand J, Zambetti G, Olson D, George D, Levine A . The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69(7):1237-45. DOI: 10.1016/0092-8674(92)90644-r. View

20.

Lowe S, Ruley H . Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 1993; 7(4):535-45. DOI: 10.1101/gad.7.4.535. View